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OBJECTIVE — To determine whether short-term improvement in pancreas graft survival
with simultaneous pancreas-kidney (SPK) transplants translated into improved long-term sur-
vival, then to examine the implications of that determination.
RESEARCH DESIGN AND METHODS — We analyzed data for 14,311 diabetic pa-
tients who received a ﬁrst SPK transplant between October 1987 and November 2007, using
Kaplan-Meier analysis for graft survival rates and Cox regression analysis for year-of-transplant
effect.
RESULTS — Overall,from1995to2004,5-yearpancreasgraftsurvivalstayedaboutthesame
(70–71%). Limiting analysis to grafts that survived more than 1 year, 5-year survival from 1987
to2004rangedfrom80to84%.With1987–1989asreference,theadjustedhazardratioforgraft
failure by year of transplant increased to 1.49 (95% CI 0.97–2.30) in 2000–2004.
CONCLUSIONS — Long-term pancreas graft survival has remained unchanged despite the
dramatic decreases in technical failures and early acute rejection rates that have contributed to
prolonged SPK graft survival.
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S
imultaneous pancreas-kidney (SPK)
transplants account for over 78% of
current pancreas allografts (1–3).
Expectations for SPK started high, espe-
cially when technical and immunosup-
pressive advances yielded marked
improvements in 1-year and 3-year graft
survival rates through 2004, as shown on
the International Pancreas Transplant
Registry (IPTR) Web site (2) and by pre-
viousstudies(3–6).Butthefocusofthese
studies, like clinical focus, has been on
relatively short-term survival. The ques-
tion remains: Has that translated into im-
proved long-term—5-year-plus—SPK
pancreas graft survival? This study’s ob-
jective was to determine the answer, then
examine the implications. We also exam-
ined causes of chronic pancreas graft dys-
function and other factors that may
inﬂuence evaluation of SPK as therapy for
diabetes.
RESEARCH DESIGN AND
METHODS— We analyzed data col-
lected by the United Network for Organ
Sharing (UNOS) for 14,311 diabetic pa-
tients who received a ﬁrst SPK transplant
between October 1987 and November
2007, including follow-up through No-
vember 2007. Patients (n  147) whose
follow-up data were missing were
excluded.
Baseline characteristics were com-
pared using the Kruskal-Wallis test for
continuous variables, the 
2 test for cate-
gorical variables, Kaplan-Meier analysis
and log-rank tests to calculate and com-
pare pancreas graft survival rates, and
Cox proportional hazard models to esti-
mate year-of-transplant effect—adjusted
for potential confounding factors of do-
nor and recipient demographics, duct
management, venous management, pres-
ervation time, and number of HLA mis-
matches.Patientsweregroupedbydateof
transplant into ﬁve eras: 1987–1989,
1990–1994, 1995–1999, 2000–2004,
and 2005–2007. Pancreas graft survival
was calculated for the full dataset,
then—to minimize effects of ﬁrst-year
technical failure and acute rejection—
recalculated for grafts surviving over 1
year. We used STATA version 9.0 (Stata,
College Station, TX) for all statistical
analyses.
RESULTS— Compared with other
era’s recipients, those in 2005–2007 were
more likely to be older (41.5  8.4 vs.
34.8  6.6 years in 1987–1989, P 
0.001) and male (63.7 vs. 58.0% in
1987–1989, P  0.003), were less likely
to be white (73.1 vs. 95.1% in 1987–
1989, P  0.001), had more donor-
recipient HLA mismatches (4.5  1.2 vs.
4.21.2in1987–1989,P0.001),and
had younger donors (25.9  10.3 vs.
27.2  1.3 years in 1987–1989, P 
0.001).
Although SPK pancreas graft sur-
vival improved signiﬁcantly between
1987 and 1995, it has not improved
since 1995 (Fig. 1A). These rates were
similarly high among recipients trans-
planted in the eras 1995–1999, 2000–
2004, and 2005–2007. Limiting
analysis to grafts surviving over 1 year,
5-year SPK survival rates after 1990
were almost identical in the different
eras (Fig. 1B), and SPK offered much
better survival than pancreas-after-
kidney (PAK) transplant and pancreas
transplant alone (PTA): 10- and 15-year
survival was 62 and 40%, respectively,
for SPK only 36 and 11% for PAK, and
32 and 18% for PTA (3).
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1 year—and after considering potential
confounders—there was a mild risk asso-
ciation (slight increase in graft-loss rate)
for recent-era transplants compared with
those in 1987–1989. By year of trans-
plant, adjusted hazard ratio for overall
loss of grafts surviving over 1 year in eras
1990–1994, 1995–1999, 2000–2004,
and 2005–2007 was 1.20 (95% CI 1.03–
1.41), 1.17 (0.99–1.39), 1.26 (1.04–
1.54),and1.49(0.97–2.30),respectively.
During the ﬁrst year, posttransplant
technical failures caused 66% of graft
losses.Asposttransplanttimeprogressed,
chronicrejectionquicklyreplacedtechni-
cal failure as the major cause of graft loss.
Chronic rejection caused 50% of graft
losses between 1–10 years and 54% after
10 years.
CONCLUSIONS — After 1990, graft
survival rates were strikingly similar dur-
ing this study’s different eras. Pancreas
survival showed no long-term improve-
ment, and risk of failure for grafts surviv-
ing over 1 year increased slightly for
recent transplants.
SPK transplantation and pancreas
transplantation in general may be under-
going clinical reevaluation. According to
the Organ Procurement and Transplanta-
tion Network (OPTN), the total number
of SPK, PAK, and PTA procedures has de-
clined each year from 1,484 in 2004 to
1,233 reported so far for 2009. With
some ﬂuctuations, SPK transplants have
declinedfrom915in2000(aspikeof924
in 2006) to 854 (so far) in 2009 (1).
Yet SPK offers distinct quality-of-life
(QOL) beneﬁts: freedom from self-
administered insulin, more stable blood
glucose levels, and no risk of hypoglyce-
mia (7–9). Furthermore, right now there
seems to be no realistic alternative that
affords the same QOL as SPK for type 1
diabetic patients with end-stage renal dis-
ease. Survival is comparable for living-
donor kidney transplants and SPK
transplants (10), but kidney transplants
alone offer diabetic individuals only mar-
ginal QOL improvement in freedom from
insulin injection or having more stable
glycemic control; and the supply of living
donor kidneys is still limited.
The 1-year-survived chronic pan-
creas graft failure rate at 10 and 15 years
was lowest with SPK (28 and 60%, re-
spectively) compared with PAK (64 and
89%) and PTA (68 and 82%) (3)—an im-
portant consideration because monitor-
ingoffunctionorbiopsyofanSPKkidney
may also provide warning of possible
pancreas graft chronic rejection early
enough for more timely and effective in-
tervention, a beneﬁt not obtained with
PAKor,obviously,PTA(11).Thispredic-
tive feature of SPK is slightly compro-
mised because, although (excluding ﬁrst-
year graft failures) 5-year pancreas and
kidney survivals were comparable (84
and 83%, respectively), 10-year survival
was 63% (pancreas) and 59% (kidney)
(3). Nevertheless, early warning should,
intuitively, result in improved long-term
graft survival. The reason it has not is be-
cause, as of now, there is no established,
even remotely deﬁnitive treatment for
chronic rejection—which, as we have
shown above, is the major long-term
cause of graft dysfunction and loss.
That leads to the real implication of
our study’s new ﬁnding. There will evi-
dently be no “natural” improvement in
long-term pancreas graft survival that
might be expected after such great short-
term improvement. So the next step must
be the same level of concentration on elu-
cidating the mechanism of chronic rejec-
tion and developing a therapy as effective
as that for reducing short-term graft loss.
Meanwhile, the clinical decision as to
whether the QOL beneﬁts and predictive
feature of SPK offset any contraindica-
tions should be weighed for each patient,
individually, and the new knowledge
that, right now, long-term survival has
not improved constituting one more fac-
tor to be weighed.
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Figure 1—A: Pancreas graft survival by era for all transplants, 1987–2007: UNOS registry analysis. B: Pancreas graft survival by era for
transplants surviving more than 1 year, 1987–2007: UNOS registry analysis.
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